Secarna Pharmaceuticals GmbH & Co. KG | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Headlines Articles Press releases Secarna Pharmaceuticals GmbH & Co. KG

Home
Companies
Secarna Pharmaceuticals GmbH & Co. KG

BRIEF

published on 07/22/2024 at 14:05, 3 months 29 days ago

Secarna Pharmaceuticals publie de nouvelles données sur les ASO modifiés par LNA

Secarna Pharmaceutique TLR9 OLS Potentiel Immunostimulateur Thérapeutique À Base D'acide Nucléique
PRESS RELEASE

published on 07/22/2024 at 14:00, 3 months 29 days ago

Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs
Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics highlighting strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs

Secarna Pharmaceuticals ASOs Immunostimulatory Potential Nucleic Acid Therapeutics LNA-modified
BRIEF

published on 05/28/2024 at 13:05, 5 months 24 days ago

Secarna Pharmaceuticals et Orbit Discovery concluent une collaboration pour développer des produits thérapeutiques antisens conjugués à des peptides

Collaboration Secarna Pharmaceutique Découverte De L'orbite Thérapeutique Antisens Conjugué Aux Peptides
BRIEF

published on 05/28/2024 at 13:05, 5 months 24 days ago

Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Develop Peptide-Conjugated Antisense Therapeutics

Collaboration Secarna Pharmaceuticals Orbit Discovery Antisense Therapeutics Peptide-Conjugated
PRESS RELEASE

published on 05/28/2024 at 13:00, 5 months 24 days ago

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics
Secarna Pharmaceuticals and Orbit Discovery collaborate to develop peptide-conjugated targeted antisense oligonucleotide therapeutics, expanding treatment options for various diseases

Collaboration Secarna Pharmaceuticals Orbit Discovery Peptide-Conjugated Antisense Oligonucleotide Therapeutics
BRIEF

published on 03/20/2024 at 14:05, 8 months ago

Celanese et Secarna Pharmaceuticals annoncent une collaboration sur le développement de thérapies antisens

Celanese Secarna Pharmaceutique Oligonucléotides Antisens L'administration De Médicaments Collaboration En Recherche
BRIEF

published on 03/20/2024 at 14:05, 8 months ago

Celanese and Secarna Pharmaceuticals Announce Collaboration on Antisense Therapy Development

Celanese Secarna Pharmaceuticals Antisense Oligonucleotides Drug Delivery Research Collaboration
PRESS RELEASE

published on 03/20/2024 at 14:00, 8 months ago

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
Celanese and Secarna Pharmaceuticals collaborate on long-acting antisense therapy implants utilizing ASOs to target specific diseases for improved patient outcomes

Celanese Secarna Pharmaceuticals Drug Delivery Antisense Therapy ASOs
PRESS RELEASE

published on 11/03/2023 at 18:05, 1 year ago

Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1
PRESS RELEASE

published on 10/25/2023 at 15:00, 1 year ago

Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs

Accesswire

Published on 11/21/2024 at 12:00, 1 hour 6 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 1 hour 6 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 36 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 3 hours 3 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 3 hours 6 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 31 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 51 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 59 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 6 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 36 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 8 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 8 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 8 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 59 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 46 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE